These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1491248)

  • 1. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
    Löschmann PA; Kunow M; Wachtel H
    J Neural Transm Suppl; 1992; 38():55-64. PubMed ID: 1491248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
    Wachtel H; Kunow M; Löschmann PA
    Neurosci Lett; 1992 Aug; 142(2):179-82. PubMed ID: 1280793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
    Löschmann PA; Lange KW; Kunow M; Rettig KJ; Jähnig P; Honoré T; Turski L; Wachtel H; Jenner P; Marsden CD
    J Neural Transm Park Dis Dement Sect; 1991; 3(3):203-13. PubMed ID: 1835581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].
    Pavón N; Vidal L; Alvarez P; Blanco L; Torres A; Rodríguez A; Macías R
    Rev Neurol; 1998 Jun; 26(154):915-8. PubMed ID: 9658459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
    J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
    O'Neill MJ; Murray TK; Whalley K; Ward MA; Hicks CA; Woodhouse S; Osborne DJ; Skolnick P
    Eur J Pharmacol; 2004 Feb; 486(2):163-74. PubMed ID: 14975705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of a small, unilateral, 6-hydroxydopamine-induced nigral lesion on behavior in high and low responders to novelty.
    van Oosten RV; Cools AR
    Exp Neurol; 2002 Feb; 173(2):245-55. PubMed ID: 11822888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.
    Da Cunha C; Wietzikoski EC; Ferro MM; Martinez GR; Vital MA; Hipólide D; Tufik S; Canteras NS
    Behav Brain Res; 2008 Jun; 189(2):364-72. PubMed ID: 18328580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
    Löschmann PA; De Groote C; Smith L; Wüllner U; Fischer G; Kemp JA; Jenner P; Klockgether T
    Exp Neurol; 2004 May; 187(1):86-93. PubMed ID: 15081591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.